Although infrequent, treatment resistance to antiretroviral therapy (ART) can occur when HIV pre-exposure prophylaxis (PrEP) HIV medications are started or continued following an undiagnosed acute HIV infection or when HIV treatment and/or adherence to treatment is suboptimal. With various PrEP and ART treatments available, clinicians require education on how to counter drug resistance, when to switch ART treatments, how to find the best treatment options for their patients, how to educate their patients on the importance of medication adherence, and how to monitor progress after switching therapies.
This CMEO BriefCase entitled, Switching Antiretroviral Therapy (ART) Due to Treatment Resistance, will discuss the specific case of an individual who experiences resistance to ART treatment. Expert faculty will discuss recognizing when treatment resistance occurs, why it may occur, and ways to switch treatments and monitor outcomes for patients experiencing treatment resistance.
Implement ART switching strategies to overcome HIV treatment resistance.
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
Primary care physicians, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists specializing in HIV.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Hagins reports no financial relationships to disclose. She is an uncompensated volunteer participant in speaker trainings, ad boards and on the speaker’s bureau for Gilead Sciences, Inc.; GSK/ViiV Healthcare; and Janssen Pharmaceuticals, inc. since July 2021.
Dr. Segal-Maurer reports the following financial relationships:
Advisory Board: Gilead Sciences, Inc.; Janssen Therapeutics; Theratechnologies Inc.; and ViiV Healthcare
Consultant: Gilead Sciences, Inc.; Janssen Therapeutics; Lumanity Inc.; Theratechnologies Inc.; Veradigm LLC; and ViiV Healthcare
Research Support: Gilead Sciences, Inc. to NYPQ (no support to Dr. Segal-Maurer)
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).